{"pmid":32503826,"title":"Tor Vergata University-Hospital in the Beginning of COVID-19-Era: Experience and Recommendation for Breast Cancer Patients.","text":["Tor Vergata University-Hospital in the Beginning of COVID-19-Era: Experience and Recommendation for Breast Cancer Patients.","COVID-19 has been officially declared as a pandemic by the WHO. Italy was the first European country to be strongly affected by this outbreak. All elective and health promotion activities were reduced. Accordingly, Italian Breast Units and breast cancer (BC) screening programs scaled down significantly their activities. The aim of this study was to evaluate measures that could potentially reduce the clinical impact of COVID-19 on BC patients. Temporary recommendations are needed that could assist specialists in preventing COVID-19 infection and optimizing resources for diagnosis and treatment of BC patients.","In Vivo","Buonomo, Oreste Claudio","Materazzo, Marco","Pellicciaro, Marco","Caspi, Jonathan","Piccione, Emilio","Vanni, Gianluca","32503826"],"abstract":["COVID-19 has been officially declared as a pandemic by the WHO. Italy was the first European country to be strongly affected by this outbreak. All elective and health promotion activities were reduced. Accordingly, Italian Breast Units and breast cancer (BC) screening programs scaled down significantly their activities. The aim of this study was to evaluate measures that could potentially reduce the clinical impact of COVID-19 on BC patients. Temporary recommendations are needed that could assist specialists in preventing COVID-19 infection and optimizing resources for diagnosis and treatment of BC patients."],"journal":"In Vivo","authors":["Buonomo, Oreste Claudio","Materazzo, Marco","Pellicciaro, Marco","Caspi, Jonathan","Piccione, Emilio","Vanni, Gianluca"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32503826","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.21873/invivo.11958","keywords":["breast cancer","covid-19","italy","screening program","tailored treatment"],"locations":["Italy","Italian"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1668892488245444608,"score":9.490897,"similar":[{"pmid":32503825,"title":"Breast Cancer and COVID-19: The Effect of Fear on Patients' Decision-making Process.","text":["Breast Cancer and COVID-19: The Effect of Fear on Patients' Decision-making Process.","BACKGROUND/AIM: Coronavirus-19 (COVID-19) pandemic outbreak is currently having a huge impact on medical resource allocation. Breast Cancer (BC) patients are concerned both with BC treatment and COVID-19. This study aimed to estimate the impact of anxiety among patients, caused by the spreading of COVID-19. PATIENTS AND METHODS: Between the 16th of January and the 20th of March 2020, we retrospectively enrolled 160 patients. Eighty-two patients with a suspected breast lesion (SBL) were divided into two groups: PRE-COVID-19-SBL and POST-COVID-19-SBL. Seventy-eight BC patients were divided into PRE-COVID-19-BC and POST-COVID-19-BC. Patient characteristics including age, marital status, SBL/BC diameter, personal and family history of BC, clinical stage and molecular subtype were recorded. Procedure Refusal (PR) and Surgical Refusal (SR) were also recorded with their reason. RESULTS: BC and SBL analysis showed no difference in pre-treatment characteristics (p>0.05). Both POST-COVID-19-SBL and POST-COVID-19-BC groups showed higher rates of PR and SR (p=0.0208, p=0.0065 respectively). Infection risk represented primary reason for refusal among POST-COVID-19 patients. CONCLUSION: COVID-19-related anxiety could affect patients' decision-making process.","In Vivo","Vanni, Gianluca","Materazzo, Marco","Pellicciaro, Marco","Ingallinella, Sara","Rho, Maurizio","Santori, Francesca","Cotesta, Maria","Caspi, Jonathan","Makarova, Anna","Pistolese, Chiara Adriana","Buonomo, Oreste Claudio","32503825"],"abstract":["BACKGROUND/AIM: Coronavirus-19 (COVID-19) pandemic outbreak is currently having a huge impact on medical resource allocation. Breast Cancer (BC) patients are concerned both with BC treatment and COVID-19. This study aimed to estimate the impact of anxiety among patients, caused by the spreading of COVID-19. PATIENTS AND METHODS: Between the 16th of January and the 20th of March 2020, we retrospectively enrolled 160 patients. Eighty-two patients with a suspected breast lesion (SBL) were divided into two groups: PRE-COVID-19-SBL and POST-COVID-19-SBL. Seventy-eight BC patients were divided into PRE-COVID-19-BC and POST-COVID-19-BC. Patient characteristics including age, marital status, SBL/BC diameter, personal and family history of BC, clinical stage and molecular subtype were recorded. Procedure Refusal (PR) and Surgical Refusal (SR) were also recorded with their reason. RESULTS: BC and SBL analysis showed no difference in pre-treatment characteristics (p>0.05). Both POST-COVID-19-SBL and POST-COVID-19-BC groups showed higher rates of PR and SR (p=0.0208, p=0.0065 respectively). Infection risk represented primary reason for refusal among POST-COVID-19 patients. CONCLUSION: COVID-19-related anxiety could affect patients' decision-making process."],"journal":"In Vivo","authors":["Vanni, Gianluca","Materazzo, Marco","Pellicciaro, Marco","Ingallinella, Sara","Rho, Maurizio","Santori, Francesca","Cotesta, Maria","Caspi, Jonathan","Makarova, Anna","Pistolese, Chiara Adriana","Buonomo, Oreste Claudio"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32503825","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.21873/invivo.11957","keywords":["covid-19","sars-sov-2","anxiety","breast cancer","decision-making process","surgery","surgery refusal"],"topics":["Prevention"],"weight":1,"_version_":1668892488273756161,"score":335.32098},{"pmid":32471115,"title":"The Network of Angiotensin Receptors in Breast Cancer.","text":["The Network of Angiotensin Receptors in Breast Cancer.","The renin-angiotensin system (RAS) is a network of proteins regulating many aspects of human physiology, including cardiovascular, pulmonary, and immune system physiology. The RAS is a complicated network of G-protein coupled receptors (GPCRs) (i.e., AT1R, AT2R, MASR, and MRGD) orchestrating the effects of several hormones (i.e., angiotensin II, angiotensin (1-7), and alamandine) produced by protease-based transmembrane receptors (ACE1 and ACE2). Two signaling axes have been identified in the RAS endocrine system that mediate the proliferative actions of angiotensin II (i.e., the AT1R-based pathway) or the anti-proliferative effects of RAS hormones (i.e., the AT2R-, MAS-, and MRGD-based pathways). Disruption of the balance between these two axes can cause different diseases (e.g., cardiovascular pathologies and the severe acute respiratory syndrome coronavirus 2- (SARS-CoV-2)-based COVID-19 disease). It is now accepted that all the components of the RAS endocrine system are expressed in cancer, including cancer of the breast. Breast cancer (BC) is a multifactorial pathology for which there is a continuous need to identify novel drugs. Here, I reviewed the possible roles of both axes of the RAS endocrine network as potential druggable pathways in BC. Remarkably, the analysis of the current knowledge of the different GPCRs of the RAS molecular system not only confirms that AT1R could be considered a drug target and that its inhibition by losartan and candesartan could be useful in the treatment of BC, but also identifies Mas-related GPCR member D (MRGD) as a druggable protein. Overall, the RAS of GPCRs offers multifaceted opportunities for the development of additional compounds for the treatment of BC.","Cells","Acconcia, Filippo","32471115"],"abstract":["The renin-angiotensin system (RAS) is a network of proteins regulating many aspects of human physiology, including cardiovascular, pulmonary, and immune system physiology. The RAS is a complicated network of G-protein coupled receptors (GPCRs) (i.e., AT1R, AT2R, MASR, and MRGD) orchestrating the effects of several hormones (i.e., angiotensin II, angiotensin (1-7), and alamandine) produced by protease-based transmembrane receptors (ACE1 and ACE2). Two signaling axes have been identified in the RAS endocrine system that mediate the proliferative actions of angiotensin II (i.e., the AT1R-based pathway) or the anti-proliferative effects of RAS hormones (i.e., the AT2R-, MAS-, and MRGD-based pathways). Disruption of the balance between these two axes can cause different diseases (e.g., cardiovascular pathologies and the severe acute respiratory syndrome coronavirus 2- (SARS-CoV-2)-based COVID-19 disease). It is now accepted that all the components of the RAS endocrine system are expressed in cancer, including cancer of the breast. Breast cancer (BC) is a multifactorial pathology for which there is a continuous need to identify novel drugs. Here, I reviewed the possible roles of both axes of the RAS endocrine network as potential druggable pathways in BC. Remarkably, the analysis of the current knowledge of the different GPCRs of the RAS molecular system not only confirms that AT1R could be considered a drug target and that its inhibition by losartan and candesartan could be useful in the treatment of BC, but also identifies Mas-related GPCR member D (MRGD) as a druggable protein. Overall, the RAS of GPCRs offers multifaceted opportunities for the development of additional compounds for the treatment of BC."],"journal":"Cells","authors":["Acconcia, Filippo"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32471115","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3390/cells9061336","keywords":["at1r","at2r","masr","mrgd","angiotensin","breast cancer"],"locations":["Breast Cancer"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1668255193468239872,"score":295.28192},{"pmid":32333293,"pmcid":"PMC7181102","title":"Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium.","text":["Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium.","The COVID-19 pandemic presents clinicians a unique set of challenges in managing breast cancer (BC) patients. As hospital resources and staff become more limited during the COVID-19 pandemic, it becomes critically important to define which BC patients require more urgent care and which patients can wait for treatment until the pandemic is over. In this Special Communication, we use expert opinion of representatives from multiple cancer care organizations to categorize BC patients into priority levels (A, B, C) for urgency of care across all specialties. Additionally, we provide treatment recommendations for each of these patient scenarios. Priority A patients have conditions that are immediately life threatening or symptomatic requiring urgent treatment. Priority B patients have conditions that do not require immediate treatment but should start treatment before the pandemic is over. Priority C patients have conditions that can be safely deferred until the pandemic is over. The implementation of these recommendations for patient triage, which are based on the highest level available evidence, must be adapted to current availability of hospital resources and severity of the COVID-19 pandemic in each region of the country. Additionally, the risk of disease progression and worse outcomes for patients need to be weighed against the risk of patient and staff exposure to SARS CoV-2 (virus associated with the COVID-19 pandemic). Physicians should use these recommendations to prioritize care for their BC patients and adapt treatment recommendations to the local context at their hospital.","Breast Cancer Res Treat","Dietz, Jill R","Moran, Meena S","Isakoff, Steven J","Kurtzman, Scott H","Willey, Shawna C","Burstein, Harold J","Bleicher, Richard J","Lyons, Janice A","Sarantou, Terry","Baron, Paul L","Stevens, Randy E","Boolbol, Susan K","Anderson, Benjamin O","Shulman, Lawrence N","Gradishar, William J","Monticciolo, Debra L","Plecha, Donna M","Nelson, Heidi","Yao, Katharine A","32333293"],"abstract":["The COVID-19 pandemic presents clinicians a unique set of challenges in managing breast cancer (BC) patients. As hospital resources and staff become more limited during the COVID-19 pandemic, it becomes critically important to define which BC patients require more urgent care and which patients can wait for treatment until the pandemic is over. In this Special Communication, we use expert opinion of representatives from multiple cancer care organizations to categorize BC patients into priority levels (A, B, C) for urgency of care across all specialties. Additionally, we provide treatment recommendations for each of these patient scenarios. Priority A patients have conditions that are immediately life threatening or symptomatic requiring urgent treatment. Priority B patients have conditions that do not require immediate treatment but should start treatment before the pandemic is over. Priority C patients have conditions that can be safely deferred until the pandemic is over. The implementation of these recommendations for patient triage, which are based on the highest level available evidence, must be adapted to current availability of hospital resources and severity of the COVID-19 pandemic in each region of the country. Additionally, the risk of disease progression and worse outcomes for patients need to be weighed against the risk of patient and staff exposure to SARS CoV-2 (virus associated with the COVID-19 pandemic). Physicians should use these recommendations to prioritize care for their BC patients and adapt treatment recommendations to the local context at their hospital."],"journal":"Breast Cancer Res Treat","authors":["Dietz, Jill R","Moran, Meena S","Isakoff, Steven J","Kurtzman, Scott H","Willey, Shawna C","Burstein, Harold J","Bleicher, Richard J","Lyons, Janice A","Sarantou, Terry","Baron, Paul L","Stevens, Randy E","Boolbol, Susan K","Anderson, Benjamin O","Shulman, Lawrence N","Gradishar, William J","Monticciolo, Debra L","Plecha, Donna M","Nelson, Heidi","Yao, Katharine A"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333293","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1007/s10549-020-05644-z","locations":["Physicians"],"topics":["Prevention"],"weight":1,"_version_":1666138494007771136,"score":284.26108},{"pmid":32503827,"title":"Breast Cancer Surgery During the COVID-19 Pandemic: An Observational Clinical Study of the Breast Surgery Clinic at Ospedale Policlinico San Martino - Genoa, Italy.","text":["Breast Cancer Surgery During the COVID-19 Pandemic: An Observational Clinical Study of the Breast Surgery Clinic at Ospedale Policlinico San Martino - Genoa, Italy.","BACKGROUND: COVID-19 pandemic required a marked re-allocation of healthcare resources, including at Breast Units. A patient-tailored program was developed to assess its efficacy regarding prevention of COVID-19 infection among patients with breast cancer undergoing surgery and healthcare workers (HCWs). PATIENTS AND METHODS: From March 9th to April 9th 2020, 91 patients were selected for elective surgery by means of: i) Pre-hospital screening aimed at avoiding hospitalization of symptomatic or suspicious COVID-19 patients, and ii) prioritisation of surgical procedure according to specific disease features. RESULTS: Eighty-five patients (93.4%) were fit for surgery, while five patients (5.5%) were temporarily excluded through 'telephone triage'; another two patients were excluded at in-hospital triage. A total of 71 out of 85 patients (83.5%) were diagnosed with invasive cancer, most of whom were undergoing breast-conserving surgery (61 out of 85 patients, 71.8%). The mean in-hospital stay was 2.2 days (SD=0.7 days). After hospital discharge, no patient needed re-admission due to post-operative complications; moreover, no COVID-19 infection among patients or HCWs was detected. CONCLUSION: Safe breast cancer surgery was accomplished for both patients and HCWs by means of a careful preoperative selection of patients and in-hospital preventative measures. This screening program can be transferred to high-volume Breast Units and it may be useful in implementing European Community recommendations for prevention of COVID-19 infection.","In Vivo","Fregatti, Piero","Gipponi, Marco","Giacchino, Maria","Sparavigna, Marco","Murelli, Federica","Toni, Maria Luisa","Calabro, Maria Teresa","Orsino, Lina","Friedman, Daniele","32503827"],"abstract":["BACKGROUND: COVID-19 pandemic required a marked re-allocation of healthcare resources, including at Breast Units. A patient-tailored program was developed to assess its efficacy regarding prevention of COVID-19 infection among patients with breast cancer undergoing surgery and healthcare workers (HCWs). PATIENTS AND METHODS: From March 9th to April 9th 2020, 91 patients were selected for elective surgery by means of: i) Pre-hospital screening aimed at avoiding hospitalization of symptomatic or suspicious COVID-19 patients, and ii) prioritisation of surgical procedure according to specific disease features. RESULTS: Eighty-five patients (93.4%) were fit for surgery, while five patients (5.5%) were temporarily excluded through 'telephone triage'; another two patients were excluded at in-hospital triage. A total of 71 out of 85 patients (83.5%) were diagnosed with invasive cancer, most of whom were undergoing breast-conserving surgery (61 out of 85 patients, 71.8%). The mean in-hospital stay was 2.2 days (SD=0.7 days). After hospital discharge, no patient needed re-admission due to post-operative complications; moreover, no COVID-19 infection among patients or HCWs was detected. CONCLUSION: Safe breast cancer surgery was accomplished for both patients and HCWs by means of a careful preoperative selection of patients and in-hospital preventative measures. This screening program can be transferred to high-volume Breast Units and it may be useful in implementing European Community recommendations for prevention of COVID-19 infection."],"journal":"In Vivo","authors":["Fregatti, Piero","Gipponi, Marco","Giacchino, Maria","Sparavigna, Marco","Murelli, Federica","Toni, Maria Luisa","Calabro, Maria Teresa","Orsino, Lina","Friedman, Daniele"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32503827","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.21873/invivo.11959","keywords":["covid-19","breast cancer","clinical management"],"locations":["Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1668892488293679104,"score":233.59694},{"pmid":32412693,"title":"Personalized risk-benefit ratio adaptation of Breast Cancer care at the epicentre of Covid-19 outbreak.","text":["Personalized risk-benefit ratio adaptation of Breast Cancer care at the epicentre of Covid-19 outbreak.","Northern Italy has been one of the European regions reporting the highest number of Covid-19 cases and deaths. The pandemic spread has challenged the National Health System (NHS), requiring re-allocation of most of the available healthcare resources to treat Covid-19 positive patients, generating a competition with other healthcare needs, including cancer. Cancer patients are at higher risk of developing critical illness after Covid-19 infection. Thus, mitigation strategies should be adopted to reduce the likelihood of infection in all cancer patients. At the same time, suboptimal care and treatments may result in worse cancer-related outcome. In this paper, we attempt to estimate the individual risk-benefit balance to define personalized strategies for optimal breast cancer management, avoiding as much as possible a general untailored approach. We discuss and report the strategies our Breast Unit adopted from the beginning of the Covid-19 outbreak to ensure the continuum of the best possible cancer care for our patients while mitigating the risk of infection, despite limited healthcare resources.","Oncologist","Viale, Giulia","Licata, Luca","Sica, Lorenzo","Zambelli, Stefania","Zucchinelli, Patrizia","Rognone, Alessia","Aldrighetti, Daniela","Di Micco, Rosa","Zuber, Veronica","Pasetti, Marcella","Di Muzio, Nadia","Rodighiero, Maria Grazia","Panizza, Pietro","Sassi, Isabella","Petrella, Giovanna","Cascinu, Stefano","Gentilini, Oreste Davide","Bianchini, Giampaolo","32412693"],"abstract":["Northern Italy has been one of the European regions reporting the highest number of Covid-19 cases and deaths. The pandemic spread has challenged the National Health System (NHS), requiring re-allocation of most of the available healthcare resources to treat Covid-19 positive patients, generating a competition with other healthcare needs, including cancer. Cancer patients are at higher risk of developing critical illness after Covid-19 infection. Thus, mitigation strategies should be adopted to reduce the likelihood of infection in all cancer patients. At the same time, suboptimal care and treatments may result in worse cancer-related outcome. In this paper, we attempt to estimate the individual risk-benefit balance to define personalized strategies for optimal breast cancer management, avoiding as much as possible a general untailored approach. We discuss and report the strategies our Breast Unit adopted from the beginning of the Covid-19 outbreak to ensure the continuum of the best possible cancer care for our patients while mitigating the risk of infection, despite limited healthcare resources."],"journal":"Oncologist","authors":["Viale, Giulia","Licata, Luca","Sica, Lorenzo","Zambelli, Stefania","Zucchinelli, Patrizia","Rognone, Alessia","Aldrighetti, Daniela","Di Micco, Rosa","Zuber, Veronica","Pasetti, Marcella","Di Muzio, Nadia","Rodighiero, Maria Grazia","Panizza, Pietro","Sassi, Isabella","Petrella, Giovanna","Cascinu, Stefano","Gentilini, Oreste Davide","Bianchini, Giampaolo"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32412693","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1634/theoncologist.2020-0316","keywords":["covid-19","sars-cov-2","breast cancer","treatment"],"topics":["Prevention"],"weight":1,"_version_":1666897318920585216,"score":210.06192}]}